Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Apremilast more efficacious in PsA patients with moderate vs high disease activity

Apremilast more efficacious in PsA patients with moderate vs high disease activity

22 Jul 2022 bởiStephen Padilla

Psoriatic arthritis (PsA) patients with moderate disease activity (MDA) at baseline who are treated with apremilast are more likely to achieve treatment targets than those with high disease activity (HDA), a recent study has shown.

22 Jul 2022
6-month secukinumab use improves outcomes in psoriatic arthritis

6-month secukinumab use improves outcomes in psoriatic arthritis

21 Jul 2022 bởiStephen Padilla

Real-world patients with psoriatic arthritis (PsA) who received and remained on secukinumab treatment for 6 months has attained minimal disease activity (MDA) and shown improvements in clinical manifestations, patient-reported outcomes, and work productivity at follow-up, reveals a study. The results are consistent with findings from clinical trials.

21 Jul 2022